RNAi Roundup: Scaringe, Back Out Front, Discusses Dharmacon s Abbott Deal and Its Strategy; Alnylam Licenses Polymer Drug Delivery IP and Hires Vincent Miles; And Others | GenomeWeb

NEW YORK, Aug. 1 - Dharmacon's new deal to provide Abbott with a library of short-interfering RNAs for drug target genes is not just another gold star for the company, according to Stephen Scaringe, who has recently taken a new title of Chief Scientific officer and co-chairman.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.